Galcanezumab Efficacy in Cluster Headache: A Systematic Review with Single-Arm Meta- Analysis
Thomas Varkey1, Natalia Arturo2, Aishwarya Koppanatham3, Aisha Rizwan4, Paweł Chochoł5, Emma Orozco6
1Banner University Medical Center, 2Faculty of Medicine, Universidad CES, 3Andhra Medical College, 4Jinnah Medical And Dental College, 5University of Warmia and Mazury in Olsztyn, 6University of New Mexico
Objective:

We aimed to conduct a Systematic Review and Single-Arm Meta-Analysis exploring the effectiveness of Galcanezumab in cluster headache, incorporating the majority of available studies.

Background:
Studies using Galcanezumab for Episodic Cluster Headache have demonstrated effectiveness in reducing headache bouts. However, the results for chronic variant have been different. The effectiveness of anti-CGPR treatments for this high-burden condition remains contentious.
Design/Methods:

We conducted a systematic search in PubMed, Scopus, and Cochrane for studies using Galcanezumab (240–300 mg) in patients with chronic or episodic cluster headache. The primary outcome was the weekly reduction in headache attacks. Secondary outcomes included the percentage of patients with more than 50% response and patient global perception of improvement (PGI-I). Statistical analysis was performed using Review Manager Web 8.0.0 (RevMan Web) and Open Meta.

Results:

258 patients were included from six studies, three of which were RCTs. The main difference was calculated from baseline attacks versus bouts after receiving treatment. The weekly reduction in headache episodes was significantly lower (MD -6.3; 95% CI -7.35, -5.24). The percentage of patients achieving a >50% response during this timeframe was 66.6% (95% CI 45.8, 87.4), and the proportion of patients reporting a PGI-I score of 'much better' or 'better' was 65.7% (95% CI 42.4, 89.1). In a sub-group analysis of the three randomized controlled trials comparing Galcanezumab to placebo, which included 358 patients, the weekly reduction in headache attacks was not significant (MD -2.45; 95% CI -4.98, 0.08).

Conclusions:

The use of Galcanezumab for cluster headache can effectively reduce the frequency of attacks after treatment compared to baseline especially during the first weeks. However, the analysis of placebo-controlled studies showed no significant reduction. Further investigations are needed in subgroups of patients who are refractory to other treatments and with a larger sample size.

10.1212/WNL.0000000000211949
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.